Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Ryan

Showing results (211-220 of 274) with videos related to

Pageof 28
Sort By:
Cancer|February 7, 2014
Mutational analysis and clinical correlation of metastatic colorectal cancerAndrea L Russo, Darrell R Borger, Jackie Szymonifka, et al.
JAMA Oncology|May 26, 2018
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical TrialJanet E Murphy, Jennifer Y Wo, David P Ryan, et al.
Journal for Immunotherapy of Cancer|October 13, 2020
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumorsAlbiruni Ra Razak, James M Cleary, Victor Moreno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomasEunice L Kwak, Janusz Jankowski, Sarah P Thayer, et al.
Annals of Surgery|December 12, 2017
Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOXTheodoros Michelakos, Ilaria Pergolini, Carlos Fernández-Del Castillo, et al.
Practical Radiation Oncology|June 26, 2018
Liver reirradiation for patients with hepatocellular carcinoma and liver metastasisSusan G R McDuff, Kyla A Remillard, Hui Zheng, et al.
The Oncologist|December 20, 2011
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotypingDarrell R Borger, Kenneth K Tanabe, Kenneth C Fan, et al.
The Lancet. Oncology|November 26, 2009
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 studyAndrew X Zhu, Jeffrey A Meyerhardt, Lawrence S Blaszkowsky, et al.
Annals of Surgery|July 11, 2020
A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: The PANAMA-scoreThomas Hank, Marta Sandini, Cristina R Ferrone, et al.
Annals of Surgery|July 14, 2020
Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic CancerToni T Seppälä, Jacquelyn W Zimmerman, Elisabetta Sereni, et al.
Pageof 28

Showing results (211-220 of 274) with videos related to

Sort By:
Pageof 28
Cancer|February 7, 2014
Mutational analysis and clinical correlation of metastatic colorectal cancerAndrea L Russo, Darrell R Borger, Jackie Szymonifka, et al.
JAMA Oncology|May 26, 2018
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical TrialJanet E Murphy, Jennifer Y Wo, David P Ryan, et al.
Journal for Immunotherapy of Cancer|October 13, 2020
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumorsAlbiruni Ra Razak, James M Cleary, Victor Moreno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomasEunice L Kwak, Janusz Jankowski, Sarah P Thayer, et al.
Annals of Surgery|December 12, 2017
Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOXTheodoros Michelakos, Ilaria Pergolini, Carlos Fernández-Del Castillo, et al.
Practical Radiation Oncology|June 26, 2018
Liver reirradiation for patients with hepatocellular carcinoma and liver metastasisSusan G R McDuff, Kyla A Remillard, Hui Zheng, et al.
The Oncologist|December 20, 2011
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotypingDarrell R Borger, Kenneth K Tanabe, Kenneth C Fan, et al.
The Lancet. Oncology|November 26, 2009
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 studyAndrew X Zhu, Jeffrey A Meyerhardt, Lawrence S Blaszkowsky, et al.
Annals of Surgery|July 11, 2020
A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: The PANAMA-scoreThomas Hank, Marta Sandini, Cristina R Ferrone, et al.
Annals of Surgery|July 14, 2020
Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic CancerToni T Seppälä, Jacquelyn W Zimmerman, Elisabetta Sereni, et al.
Pageof 28